Cargando…

Multicenter, Single-Arm, Phase IV Study of Combined Aspirin and High-Dose “IVIG-SN” Therapy for Pediatric Patients with Kawasaki Disease

BACKGROUND AND OBJECTIVES: Intravenous immunoglobulin-SN (IVIG-SN) is a new human immunoglobulin product. Its safety is ensured by pathogen-elimination steps comprising solvent/detergent treatment and a nanofiltration process. This multicenter clinical study was designed to evaluate the efficacy and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoon, Kyung Lim, Lee, Hae Yong, Yu, Jeong Jin, Lee, Jae Young, Han, Mi Young, Kim, Ki Yong, Huh, June
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Cardiology 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378027/ https://www.ncbi.nlm.nih.gov/pubmed/28382076 http://dx.doi.org/10.4070/kcj.2016.0139

Ejemplares similares

Methylprednisolone Pulse Therapy or Additional IVIG for Patients with IVIG-Resistant Kawasaki Disease
por: Wang, Zhouping, et al.
Publicado: (2020)

Correlation between the Level of Inflammatory Cytokines and Prognosis in Children with IVIG-sensitive Kawasaki Disease and IVIG-resistant Kawasaki Disease
por: Zhang, Hao, et al.
Publicado: (2022)

Is High-Dose Aspirin Necessary in the Acute Phase of Kawasaki Disease?
por: Lee, Goni, et al.
Publicado: (2013)

Therapeutic Window of Intravenous Immunoglobulin (IVIG) and its correlation with IVIG-resistant in Kawasaki Disease: a retrospective study
por: Cai, Jiang Hui, et al.
Publicado: (2022)

Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease
por: Han, Chun-Ling, et al.
Publicado: (2018)

A Case of Kawasaki Disease with Coronary Aneurysm Responding to the 4th IVIG Treatment
por: Kim, Ju Young, et al.
Publicado: (2014)

A Comparative Study of IVIG versus IVIG with IV Methylprednisolone in Guillain–Barre Syndrome
por: Bhattiprolu, Rahi Kiran, et al.
Publicado: (2020)

Factors Predicting Resistance to Intravenous Immunoglobulin and Coronary Complications in Kawasaki Disease: IVIG Resistance in Kawasaki Disease
por: Han, Ji Whan
Publicado: (2017)

Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol
por: Eleftheriou, Despina, et al.
Publicado: (2023)

Profile of resistance to IVIG treatment in patients with Kawasaki disease and concomitant infection
por: Dionne, Audrey, et al.
Publicado: (2018)

Current pharmacological intervention and development of targeting IVIG resistance in Kawasaki disease
por: Zhang, Rui Long, et al.
Publicado: (2020)

Predicting Factors for Refractory Kawasaki Disease
por: Do, Young-Sun, et al.
Publicado: (2010)

DC-SIGN gene promoter variants and IVIG treatment response in Kawasaki disease
por: Portman, Michael A, et al.
Publicado: (2013)

Clinical characteristics of hemophagocytic lymphohistiocytosis following Kawasaki disease: differentiation from recurrent Kawasaki disease
por: Kang, Hae-Ryong, et al.
Publicado: (2013)

Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review
por: Crayne, Courtney B., et al.
Publicado: (2019)

Chronic, eventually fatal, Kawasaki-like disease in an adult with spondylarthropathy responding to IVIG therapy
por: Soltner, Elise, et al.
Publicado: (2009)

An Update on Reports of Atypical Presentations of Kawasaki Disease and the Recognition of IVIG Non-Responder Children
por: Conte, Cristiano, et al.
Publicado: (2023)

Elevated Serum Levels of IL-21 in Kawasaki Disease
por: Bae, Yon Jung, et al.
Publicado: (2012)

Consortium-Based Genetic Studies of Kawasaki Disease in Korea: Korean Kawasaki Disease Genetics Consortium
por: Lee, Jong-Keuk, et al.
Publicado: (2015)

Association between P2RY12 Gene Polymorphisms and IVIG Resistance in Kawasaki Patients
por: Wang, Zhouping, et al.
Publicado: (2020)

Distinctive serum lipidomic profile of IVIG-resistant Kawasaki disease children before and after treatment
por: Chen, Zhen, et al.
Publicado: (2023)

The “Intermediate” CD14 + CD16 + monocyte subpopulation plays a role in IVIG responsiveness of children with Kawasaki disease
por: Kim, Yi Seul, et al.
Publicado: (2021)

Eczematous reaction to IVIG for the treatment of dermatomyositis()()
por: Berk-Krauss, J., et al.
Publicado: (2018)

A case of rectal ulcers during aspirin therapy in acute Kawasaki disease
por: Han, Yong, et al.
Publicado: (2020)

Clinical characteristics of Kawasaki disease with sterile pyuria
por: Choi, Ja Yun, et al.
Publicado: (2013)

Increased Pentraxin 3 Levels Correlate With IVIG Responsiveness and Coronary Artery Aneurysm Formation in Kawasaki Disease
por: Kitoh, Toshiyuki, et al.
Publicado: (2021)

Mycoplasma pneumoniae infection in patients with Kawasaki disease
por: Lee, Mi Na, et al.
Publicado: (2011)

Establishment of Kawasaki disease database based on metadata standard
por: Park, Yu Rang, et al.
Publicado: (2016)

Relationship Between Gallbladder Distension and Lipid Profiles in Kawasaki Disease
por: Kim, Ki-Won, et al.
Publicado: (2010)

Effect of different doses of aspirin on the prognosis of Kawasaki disease
por: Wang, Jinxin, et al.
Publicado: (2020)

Catastrophic Kawasaki disease unresponsive to IVIG in a 3-month-old infant: a diagnostic and therapeutic challenge
por: de Magalhães, Cristina Medeiros Ribeiro, et al.
Publicado: (2012)

Decreased Steroid Hormone Receptor NR4A2 Expression in Kawasaki Disease Before IVIG Treatment
por: Huang, Ying-Hsien, et al.
Publicado: (2019)

Functional benefits of corticosteroid and IVIG combination therapy in a coronary artery endothelial cell model of Kawasaki disease
por: Inoue, Takashi, et al.
Publicado: (2020)

Clinical implications of procalcitonin in Kawasaki disease: a useful candidate for differentiating from sepsis and evaluating IVIG responsiveness
por: Niu, Man Man, et al.
Publicado: (2021)

Tenascin-C predicts IVIG non-responsiveness and coronary artery lesions in kawasaki disease in a Chinese cohort
por: Li, Yujie, et al.
Publicado: (2022)

Insertion/Deletion Polymorphism of Angiotensin Converting Enzyme Gene in Kawasaki Disease
por: Shim, Yoon Hee, et al.
Publicado: (2006)

Major methylation alterations on the CpG markers of inflammatory immune associated genes after IVIG treatment in Kawasaki disease
por: Li, Sung-Chou, et al.
Publicado: (2016)

PTX3 promotes IVIG resistance-induced endothelial injury in Kawasaki disease by regulating the NF-κB pathway
por: Sun, Ye, et al.
Publicado: (2023)

Clinical characteristics and correlation analysis of IVIG resistance in children with kawasaki disease complicated with hip synovitis: case-control study
por: Wang, Jianjie, et al.
Publicado: (2023)

Interleukin-21 Receptor Gene Polymorphisms in Kawasaki Disease
por: Kim, Mi Hyun, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_47kc3t15na6nohh7dfvtmchrre